皿治林联合润燥止痒胶囊治疗慢性荨麻疹的疗效观察

摘要

Objective To investigate the clinical effect and safety when Mizolastine was combined with the capsule of Runzaozhiyang to cure the chronic urticarial. Methods The 110 cases were divided into two groups, one was the observation group, Mizolastine and the capsule of Runzaozhiyang were taken orally by the patients from the observation group, and the dose was 10mg once a daily and 4 capsules one time, 3 times per day for Mizolastine and the capsule of Runzaozhiyang, respectively. The other group was the check, 54 cases were only fed with the Mizolastine, the usage and dose was same as that of test group. The observation lasted for 4 weeks continuously and the effect was evaluated based on the clinical symptoms, the decrease exponent of physical sign after one week, two weeks, and four weeks. Results The cure rate in observation group was 92.86%, and the control group was 74.07%. The difference was signiifcant (P<0.05). Conclusion The therapy of Mizolastine combined with the capsule of Runzaozhiyang to cure the chronic urticarial can get a better curative effects and this therapy has a little side-effects and good compliance.%目的：观察皿治林联合润燥止痒胶囊治疗慢性荨麻疹的临床疗效及安全性。方法将入选的110例慢性荨麻疹患者随机分为2组，试验组56例，给予皿治林10 mg/d口服，润燥止痒胶囊4粒，3次/日，口服。对照组54例，只给皿治林口服，用法用量同试验组。2组均连续用药4周，并分别在1周、2周、4周根据治疗前后患者的临床症状、体征下降指数进行疗效评估。结果试验组有效率92.86%，对照组74.07%，2组对比差异有统计学意义（P<0.05）。结论皿治林联合润燥止痒胶囊治疗慢性荨麻疹的疗效高，不良反应小，病人依从性好。